Fig. 6.

NOX5 promotes ESCC progression in vivo. a, b KYSE30 (a) and KYSE410 (b) cells stably expressing NOX5 or shNOX5 or their respective control vector were subcutaneously inoculated into mice (n = 5 biologically independent mice per group). The growth curves and representative images of tumor were shown. c A lung colonization model was established in mice by injecting intravenously with the indicated cells via lateral tail veins (n = 5 biologically independent mice per group). Representative H&E staining of lungs and the number of metastatic nodes on the surface of the lungs were shown. Magnification, ×1 as indicated. d, e IHC analysis of Ki-67 and CD31 in KYSE30 (d) and KYSE410 (e) tumors stably expressing NOX5 or shNOX5 or their respectively control vector. Magnification, ×10 as indicated. f, g Statistical analyses of the expression of Ki-67 (f), or CD31 (g) in the tumor tissues of KYSE30 (left panel) and KYSE410 (right panel) cells stably expressing NOX5 or shNOX5 or their respective control vector. h, i KYSE30 (h) (n = 4 biologically independent mice per group) and KYSE410 (i) (n = 5 biologically independent mice per group) cells stably overexpressing NOX5 plasmid were subcutaneously inoculated into mice treated with dasatinib (30 mg/kg/day, per os) or control solvent. The growth curves and representative images of tumor were shown. j IHC analyses of the expression of Ki-67, or CD31 in the indicated tumor tissues. **P < 0.01; ***P < 0.001; two-tailed unpaired Student’s t-test. Error bars represent mean ± SD of five independent experiments